Human Papilloma Virüsü (HPV) ve Klinik Önemi

Stanley M. (2010). HPV-immune response to infection and vaccination. Infectious Agents and Cancer, 5(1), 19.

Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. (2002). The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology, 55(4), 244-265.

World Health Organization. (2020). Human papillomavirus (HPV) and cervical cancer. WHO Fact Sheet.

Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. (2010). Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. Journal of Infectious Diseases, 202(12), 1789-1799.

Moscicki AB, Schiffman M, Kjaer S, Villa LL. (2006). Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine, 24(S3), S42-S51.

Bzhalava D, Eklund C, Dillner J. (2015). International standardization and classification of human papillomavirus types. Virology, 476, 341-344.

Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Meijer CJ, Franceschi S. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine, 348(6), 518-527.

Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. (2007). Human papillomavirus and cervical cancer. The Lancet, 370(9590), 890-907.

Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R. (2008). Distinct risk factor profiles for human papillomavirus type 16–positive and human papillomavirus type 16–negative head and neck cancers. Journal of the National Cancer Institute, 100(6), 407-420.

Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. (2012). The biology and life-cycle of human papillomaviruses. Vaccine, 30, F55-F70.

McLaughlin-Drubin ME, Munger K. (2009). The human papillomavirus E7 oncoprotein. Virology, 384(2), 335-344.

Lacey CJ, Lowndes CM, Shah KV. (2006). Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine, 24, S3/35-S3/41.

Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E. (2009). Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent HPV (types 6, 11, 16, and 18) vaccine. The Journal of Infectious Diseases, 199(6), 805-814.

Kyrgiou M, Mitra A, Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W. (2015). Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ, 349.

Harper DM, DeMars LR. (2017). HPV vaccines–A review of the first decade. Gynecologic Oncology, 146(1), 196-204.

Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. (2020). Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecologic Oncology, 159(2), 422-428.

Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, Schünemann H, Paraskevaidis E, Arbyn M. (2017). Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database of Systematic Reviews, (8).

Moscicki AB, Schiffman M, Kjaer S, Villa LL. (2006). Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine, 24(S3), S42-S51.

Kyrgiou M, Mitra A, Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W. (2015). Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ, 349.

Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E. (2009). Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent HPV (types 6, 11, 16, and 18) vaccine. The Journal of Infectious Diseases, 199(6), 805-814.

Harper DM, DeMars LR. (2017). HPV vaccines–A review of the first decade. Gynecologic Oncology, 146(1), 196-204.

Markowitz LE, Gee J, Chesson H, Stokley S. (2018). Ten years of human papillomavirus vaccination in the United States. Pediatrics, 142(2), e20173967.

Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. (2020). Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health, 8(2), e191-e203.

Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Amini S, Simmons B. (2020). Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. The Lancet, 395(10224), 575-590.

Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, Burger EA, Smith MA, Elsheikh F, Bénard É, Sy S, Regan C, Boily MC. (2020). Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. The Lancet, 395(10224), 591-603.

Stanley M. (2010). HPV-immune response to infection and vaccination. Infectious Agents and Cancer, 5(1), 19.

Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. (2002). The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology, 55(4), 244-265.

World Health Organization. (2020). Human papillomavirus (HPV) and cervical cancer. WHO Fact Sheet.

Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. (2010). Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. Journal of Infectious Diseases, 202(12), 1789-1799.

Moscicki AB, Schiffman M, Kjaer S, Villa LL. (2006). Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine, 24(S3), S42-S51.

Bzhalava D, Eklund C, Dillner J. (2015). International standardization and classification of human papillomavirus types. Virology, 476, 341-344.

Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Meijer CJ, Franceschi S. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine, 348(6), 518-527.

Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. (2007). Human papillomavirus and cervical cancer. The Lancet, 370(9590), 890-907.

Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R. (2008). Distinct risk factor profiles for human papillomavirus type 16–positive and human papillomavirus type 16–negative head and neck cancers. Journal of the National Cancer Institute, 100(6), 407-420.

Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. (2012). The biology and life-cycle of human papillomaviruses. Vaccine, 30, F55-F70.

McLaughlin-Drubin ME, Munger K. (2009). The human papillomavirus E7 oncoprotein. Virology, 384(2), 335-344.

Lacey CJ, Lowndes CM, Shah KV. (2006). Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine, 24, S3/35-S3/41.

Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E. (2009). Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent HPV (types 6, 11, 16, and 18) vaccine. The Journal of Infectious Diseases, 199(6), 805-814.

Kyrgiou M, Mitra A, Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W. (2015). Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ, 349.

Harper DM, DeMars LR. (2017). HPV vaccines–A review of the first decade. Gynecologic Oncology, 146(1), 196-204.

Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. (2020). Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecologic Oncology, 159(2), 422-428.

Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, Schünemann H, Paraskevaidis E, Arbyn M. (2017). Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database of Systematic Reviews, (8).

Moscicki AB, Schiffman M, Kjaer S, Villa LL. (2006). Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine, 24(S3), S42-S51.

Kyrgiou M, Mitra A, Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W. (2015). Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ, 349.

Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E. (2009). Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent HPV (types 6, 11, 16, and 18) vaccine. The Journal of Infectious Diseases, 199(6), 805-814.

Harper DM, DeMars LR. (2017). HPV vaccines–A review of the first decade. Gynecologic Oncology, 146(1), 196-204.

Markowitz LE, Gee J, Chesson H, Stokley S. (2018). Ten years of human papillomavirus vaccination in the United States. Pediatrics, 142(2), e20173967.

Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. (2020). Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health, 8(2), e191-e203.

Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Amini S, Simmons B. (2020). Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. The Lancet, 395(10224), 575-590.

Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, Burger EA, Smith MA, Elsheikh F, Bénard É, Sy S, Regan C, Boily MC. (2020). Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. The Lancet, 395(10224), 591-603.